icosavax is focused on developing safe and effective vaccines against infectious diseases that address important unmet medical needs and reduce healthcare costs. the company was founded on breakthrough computationally-designed virus like particle technology, exclusively licensed for a variety of infectious disease indications from the institute for protein design at the university of washington. icosavax is located in seattle.
Company profile
Ticker
ICVX
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
ICVX stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
1 Mar 24
SC TO-T/A
Third party tender offer statement (amended)
21 Feb 24
EFFECT
Notice of effectiveness
21 Feb 24
25-NSE
Exchange delisting
20 Feb 24
S-8 POS
Registration of securities for employees (post-effective amendment)
20 Feb 24
POS AM
Prospectus update (post-effective amendment)
20 Feb 24
8-K
Completion of Acquisition or Disposition of Assets
20 Feb 24
SC 14D9/A
Tender offer solicitation (amended)
20 Feb 24
SC TO-T/A
Third party tender offer statement (amended)
20 Feb 24
SC TO-T/A
Third party tender offer statement (amended)
14 Feb 24
Latest ownership filings
SC 13D/A
Qiming U.S. Healthcare GP II, LLC
21 Feb 24
SC 13D/A
RA CAPITAL MANAGEMENT, L.P.
21 Feb 24
4
Rajeev M. Shah
20 Feb 24
4
Adam K. Simpson
20 Feb 24
4
Amin Khan
20 Feb 24
4
Ann M Veneman
20 Feb 24
4
Cassia Cearley
20 Feb 24
4
HEIDI FIELDS
20 Feb 24
4
Jim Wassil
20 Feb 24
4
Thomas Joseph Russo
20 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 63.24 mm | 63.24 mm | 63.24 mm | 63.24 mm | 63.24 mm | 63.24 mm |
Cash burn (monthly) | 30.61 mm | 193.92 k | 8.43 mm | 8.82 mm | 6.32 mm | 5.96 mm |
Cash used (since last report) | 210.05 mm | 1.33 mm | 57.81 mm | 60.55 mm | 43.39 mm | 40.87 mm |
Cash remaining | -146.81 mm | 61.91 mm | 5.43 mm | 2.69 mm | 19.84 mm | 22.37 mm |
Runway (months of cash) | -4.8 | 319.3 | 0.6 | 0.3 | 3.1 | 3.8 |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 64 |
Opened positions | 10 |
Closed positions | 12 |
Increased positions | 28 |
Reduced positions | 14 |
13F shares | Current |
---|---|
Total value | 373.95 bn |
Total shares | 50.74 mm |
Total puts | 42.60 k |
Total calls | 45.80 k |
Total put/call ratio | 0.9 |
Largest owners | Shares | Value |
---|---|---|
FMR | 6.70 mm | $66.56 bn |
Ra Capital Management | 5.96 mm | $59.22 bn |
T. Rowe Price Investment Management | 4.94 mm | $49.01 mm |
TCG Crossover GP I | 3.70 mm | $34.48 mm |
TCG Crossover Management | 3.70 mm | $36.78 bn |
Qiming U.S. Ventures Management | 3.51 mm | $34.86 bn |
SNY Sanofi | 3.16 mm | $81.85 mm |
Platinum Investment Management | 2.34 mm | $23.19 bn |
Citadel Advisors | 2.19 mm | $21.70 bn |
Adams Street Partners | 2.18 mm | $21.66 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
19 Feb 24 | Mcdade Mark | Common Stock | Dispose U | Yes | No | 0 | 3,510,228 | 0.00 | 0 | |
19 Feb 24 | Mcdade Mark | Common Stock | Dispose U | No | No | 0 | 55,786 | 0.00 | 0 | |
19 Feb 24 | Mcdade Mark | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 9.89 | 17,000 | 168.13 k | 0 |
19 Feb 24 | Mcdade Mark | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 6.25 | 22,278 | 139.24 k | 0 |
19 Feb 24 | Russo Thomas Joseph | Common Stock | Dispose U | No | No | 0 | 39,367 | 0.00 | 0 | |
19 Feb 24 | Russo Thomas Joseph | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 17.55 | 74,500 | 1.31 mm | 0 |
19 Feb 24 | Russo Thomas Joseph | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 15 | 97,500 | 1.46 mm | 0 |
19 Feb 24 | Russo Thomas Joseph | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 9.06 | 125,000 | 1.13 mm | 0 |
19 Feb 24 | Russo Thomas Joseph | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 7.44 | 376,590 | 2.80 mm | 0 |
19 Feb 24 | Russo Thomas Joseph | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 2.47 | 100,000 | 247.00 k | 0 |
Press releases
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates ICVX, PGTI, IONM
12 Feb 24
INVESTIGATION ALERT: Halper Sadeh LLC Investigates CSTR, ICVX, BATL
2 Feb 24
Kuehn Law Encourages ICVX, CSTR, AVRO, and CALB Investors to Contact Law Firm
1 Feb 24
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates CSTR, EGLE, ICVX
29 Jan 24
ICOSAVAX INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Icosavax, Inc. - ICVX
26 Jan 24